This article is more than 5 years old. Information may no longer be current.

Pfizer reports increase in 2006 ophthalmology revenues

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer reported worldwide ophthalmology revenues of $1.46 billion for 2006, up 6% from 2005. The increase was almost entirely driven by sales of the glaucoma medications Xalatan (latanoprost) and Xalacom (timolol and latanoprost).

Ophthalmology revenues experienced the sharpest increase within the United States, rising 12% over 2005 to $483 million, according to the company's earnings release.